Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.83
+0.18 (2.08%)
Feb 19, 2026, 2:22 PM EST - Market open
Zevra Therapeutics Employees
Zevra Therapeutics had 59 employees as of December 31, 2024. The number of employees decreased by 10 or -14.49% compared to the previous year.
Employees
59
Change (1Y)
-10
Growth (1Y)
-14.49%
Revenue / Employee
$1,430,305
Profits / Employee
$508,746
Market Cap
497.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 59 | -10 | -14.49% | 59 | 0 |
| Dec 31, 2023 | 69 | 33 | 91.67% | 65 | 4 |
| Dec 31, 2022 | 36 | 12 | 50.00% | 32 | 4 |
| Dec 31, 2021 | 24 | 2 | 9.09% | 24 | 0 |
| Dec 31, 2020 | 22 | 0 | - | 22 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Allogene Therapeutics | 229 |
| 4D Molecular Therapeutics | 227 |
| Prothena Corporation | 163 |
| Gossamer Bio | 145 |
| Ocugen | 95 |
| Keros Therapeutics | 82 |
| Lexeo Therapeutics | 61 |
| PepGen | 57 |
ZVRA News
- 3 hours ago - Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 1 day ago - Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Business Wire
- 15 days ago - Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ - GlobeNewsWire
- 17 days ago - Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 - GlobeNewsWire
- 24 days ago - Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ - GlobeNewsWire
- 4 weeks ago - Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market - Seeking Alpha
- 2 months ago - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire